Conference for Asia Pacific Psychedelic Science

Australia is at the centre of this shift. In 2020, Monash University established the country's first dedicated psychedelic research lab. In 2023, the Therapeutic Goods Administration created a regulated pathway for authorised psychiatrists to prescribe MDMA and psilocybin, making Australia one of the first countries to formalise clinical access to psychedelic-assisted therapy outside of clinical trials.

Multiple groups across the Asia-Pacific are now conducting world-first and world-class psychedelic research, assessing implementation in real-world clinics, asking questions across a diverse array of disciplines, manufacturing psychedelic compounds in novel ways, shaping novel policy, and developing psychedelic practice.

CAPS27 builds on that foundation. It's a forum for researchers, clinicians, policymakers, ethicists, cultural scholars, educators, industry leaders, and funders to meet, share evidence, build collaborations, and advance the field together.